Loading...
Market
What will be Fibromun's market share in the global anti-cancer immunotherapy market by end of 2025?
2
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Market research reports and Sun Pharma's financial disclosures
Story
Sun Pharma and Philogen Sign Exclusive Deal to Commercialize Anti-Cancer Drug Fibromun
Oct 1, 2024, 08:52 AM
Sun Pharma has entered into an exclusive global commercialization, licensing, and supply agreement with Swiss-Italian company Philogen to commercialize Fibromun, a specialty cancer anti-cancer immunotherapy drug. This partnership aims to leverage Sun Pharma's extensive market reach to bring Fibromun to a broader range of patients worldwide.
View original story
Similar markets
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Ivonescimab > Keytruda • 25%
Ivonescimab = Keytruda • 25%
Ivonescimab < Keytruda • 25%
Neither has significant market share • 25%
Tecentriq Hybreza gains the most market share • 25%
Keytruda gains the most market share • 25%
Opdivo gains the most market share • 25%
Other treatment gains the most market share • 25%
Less than 5% • 25%
5% - 10% • 25%
10% - 15% • 25%
More than 15% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% • 33%
10% to 20% • 33%
More than 20% • 34%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%